The Ovarian Cancer Market is expected to grow at a 10.5% CAGR during the forecast period for 2024-2031.
Ovarian cancer rank fifth in cancer deaths among women and accounting for more deaths than any other cancer of the female reproductive system. Previously it believed that cancer begin only in the ovaries, but recent evidence suggests that many ovarian cancer may start in the fallopian tubes. Factors can increase risk of cancer include older age, genetic mutation such as breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2) and oestrogen hormone replacement therapy. Based on cell of origin ovarian cancer can categorised into three type epithelial tumors, stromal tumors and germ cell tumors. Epithelial tumors begins epithelia tissue of ovarian and it comprise 90% of the ovarian cancers whereas stromal tumors begin from the hormone-producing cell of the ovaries and consist of 7% of the ovarian cancers. According to global estimate 225,000 new cases were detected each year and 140,000 people annually die from the ovarian cancer.
Treatment of ovarian cancer depending on its type and stage. Two types of treatment offer for a patient with ovarian cancer patients include local treatment and systematic treatment. Local treatment consists of surgery and radiation therapy whereas systematic treatment include chemotherapy, hormone therapy and targeted therapy. Successful development of new targeted therapy and recent approval of Avastin (Bevacizumab) and PARP inhibitor such as rubraca (rucaparib), lynparza (olaparib) and zijula (niraparib) will drive the market in forecast period. Additionally, new understanding of the heterogeneity and biology of disease lead to active development of next-generation chemotherapies, new targeted agents and immune-oncology drugs anticipated to further drive market growth.
In January, 2016 The UK National Institute for Health and Care Excellence (NICE) approve AstraZeneca drug Lynparza (olaparib) to treat women with platinum-sensitive relapsed BRAC-mutated high grade ovarian cancer. In July 2018, on the basis of phase 3 trial dubbed GOG -0213, Roche get expanded reimbursement for ovarian cancer therapy. The Avastin previously gained coverage to be used with carboplatin and paclitaxel as first-line combination treatment for patients with high relapsed ovarian cancer. It was also reimburse for use with topotecan or paclitaxel or PEGylated liposomal doxorubicin in platinum resistance ovarian cancer patient who have not previously treated with VEGF-based therapy.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 10.5% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Treatment |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Pfizer Inc. Fresenius Kabi USA, LLC, Teva Pharmaceuticals USA, Inc., F. Hoffmann-La Roche AG. AstraZeneca, Tesaro Inc. Clovis Oncology, Inc., and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Ovarian Cancer Market Snapshot
Chapter 4. Global Ovarian Cancer Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Treatment Estimates & Trend Analysis
5.1. By Treatment & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Treatment:
5.2.1. Chemotherapy
5.2.2. Targeted Therapy
5.2.3. Hormonal Therapy
5.2.4. Surgery
Chapter 6. Ovarian Cancer Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Ovarian Cancer Market revenue (US$ Million) estimates and forecasts By Treatment, 2024 - 2031
6.1.2. North America Ovarian Cancer Market revenue (US$ Million) estimates and forecasts by country, 2024 - 2031
6.2. Europe
6.2.1. Europe Ovarian Cancer Market revenue (US$ Million) By Treatment, 2024 - 2031
6.2.2. Europe Ovarian Cancer Market revenue (US$ Million) by country, 2024 - 2031
6.3. Asia Pacific
6.3.1. Asia Pacific Ovarian Cancer Market revenue (US$ Million) By Treatment, 2024 - 2031
6.3.2. Asia Pacific Ovarian Cancer Market revenue (US$ Million) by country, 2024 - 2031
6.4. Latin America
6.4.1. Latin America Ovarian Cancer Market revenue (US$ Million) By Treatment, 2024 - 2031
6.4.2. Latin America Ovarian Cancer Market revenue (US$ Million) by country, 2024 - 2031
6.5. Middle East & Africa
6.5.1. Middle East & Africa Ovarian Cancer Market revenue (US$ Million) By Treatment, 2024 - 2031
6.5.2. Middle East & Africa Ovarian Cancer Market revenue (US$ Million) by country, 2024 - 2031
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Pfizer Inc
7.2.2. Fresenius Kabi USA, LLC
7.2.3. Teva Pharmaceuticals USA, Inc
7.2.4. F. Hoffmann-La Roche AG
7.2.5. AstraZeneca
7.2.6. Tesaro Inc
7.2.7. Clovis Oncology, Inc.
7.2.8. Other Key Players
Global Ovarian Cancer Market Outlook By Treatment
Global Ovarian Cancer Market Outlook By Region
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
